CV (cardiovascular) device incubator looking to create 6 new companies - update
This article was originally published in Clinica
Executive Summary
Up to six new companies will be created to develop cardiovascular devices under the aegis of Accelerated Technologies Inc (ATI), a New York-based medtech incubator. ATI has just raised $32m in venture financing in equal parts from venture capital firms US-based Oxford Bioscience Partners, Dutch ABN AMRO Capital and Giza Venture Capital (Israel).
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.